A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components

The Sequence Alignment/Map format and SAMtools

Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041

Fast and accurate short read alignment with Burrows-Wheeler transform

Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625

ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data

Wang, K., Li, M., & Hakonarson, H. H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,724

Fast and accurate long-read alignment with Burrows-Wheeler transform.

Li, H., & Durbin, R. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp698 · Cited by 12,063

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261

Comprehensive molecular profiling of lung adenocarcinoma

The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525

Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer

Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489

VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencingPreprint

Koboldt, D. C., Zhang, Q., Larson, D. E., Shen, D., McLellan, M. D., Lin, L., Miller, C. A., Mardis, E. R., Ding, L., & Wilson, R. K. (2012) · Genome Research · doi:10.1101/gr.129684.111 · Cited by 4,954

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496

EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 1×

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379

The spindle-assembly checkpoint in space and time

Musacchio, A., & Salmon, E. D. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2163 · Cited by 2,227

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Bean, J., Brennan, C., Shih, J.-Y., Riely, G., Viale, A., Wang, L., Chitale, D., Motoi, N., Szoke, J., Broderick, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710370104 · Cited by 1,598

Genetic and pharmacological disruption of the TEAD–YAP complex suppresses the oncogenic activity of YAP

Liu-Chittenden, Y., Huang, B., Shim, J. S., Chen, Q., Lee, S.-J., Anders, R. A., Liu, J. O., & Pan, D. (2012) · Genes & Development · doi:10.1101/gad.192856.112 · Cited by 1,452

The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells

Cordenonsi, M., Zanconato, F., Azzolin, L., Forcato, M., Rosato, A., Frasson, C., Inui, M., Montagner, M., Parenti, A. R., Poletti, A., et al. (2011) · Cell · doi:10.1016/j.cell.2011.09.048 · Cited by 1,381

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

Zhang, Z., Lee, J. C., Lin, L., Olivas, V., Au, V., LaFramboise, T., Abdel-Rahman, M., Wang, X., Levine, A. D., Rho, J. K., et al. (2012) · Nature Genetics · doi:10.1038/ng.2330 · Cited by 1,224

An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Byers, L. A., Diao, L., Wang, J., Saintigny, P., Girard, L., Peyton, M., Shen, L., Fan, Y., Giri, U., Tumula, P. K., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1558 · Cited by 1,059

Reassessing Epithelial to Mesenchymal Transition as a Prerequisite for Carcinoma Invasion and Metastasis

Christiansen, J. J., & Rajasekaran, A. K. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0410 · Cited by 1,051

Epithelial Plasticity: A Common Theme in Embryonic and Cancer Cells

Nieto, M. A. (2013) · Science · doi:10.1126/science.1234850 · Cited by 991

Akt Phosphorylates the Yes-Associated Protein, YAP, to Induce Interaction with 14-3-3 and Attenuation of p73-Mediated Apoptosis

Basu, S., Totty, N. F., Irwin, M. S., Sudol, M., & Downward, J. (2003) · Molecular Cell · doi:10.1016/s1097-2765(02)00776-1 · Cited by 843

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations

Sequist, L. V., Martins, R. G., Spigel, D., Grunberg, S. M., Spira, A., Jänne, P. A., Joshi, V. A., McCollum, D., Evans, T. L., Muzikansky, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8494 · Cited by 820

HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation

Takezawa, K., Pirazzoli, V., Arcila, M. E., Nebhan, C. A., Song, X., de Stanchina, E., Ohashi, K., Janjigian, Y. Y., Spitzler, P. J., Melnick, M. A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0108 · Cited by 710

Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib

Oxnard, G. R., Hu, Y., Mileham, K. F., Husain, H., Costa, D. B., Tracy, P., Feeney, N., Sholl, L. M., Dahlberg, S. E., Redig, A. J., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2969 · Cited by 686

Epithelial to Mesenchymal Transition Is a Determinant of Sensitivity of Non–Small-Cell Lung Carcinoma Cell Lines and Xenografts to Epidermal Growth Factor Receptor Inhibition

Thomson, S., Buck, E. A., Petti, F., Griffin, G., Brown, E., Ramnarine, N., Iwata, K. K., Gibson, N. W., & Haley, J. D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1058 · Cited by 663

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

Niederst, M. J., Sequist, L. V., Poirier, J. T., Mermel, C. H., Lockerman, E. L., Garcia, A. R., Katayama, R., Costa, C., Ross, K. N., Moran, T., et al. (2015) · Nature Communications · doi:10.1038/ncomms7377 · Cited by 647

Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non–Small-Cell Lung Cancer: Current Knowledge and Future Directions

Pao, W. J., & Miller, V. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.799 · Cited by 637

Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase

Wang, I.-C., Chen, Y.-J., Hughes, D., Petrovic, V., Major, M. L., Park, H. J., Tan, Y., Ackerson, T., & Costa, R. H. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.24.10875-10894.2005 · Cited by 627

The transcription factor ZEB1 (δEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity

Aigner, K., Dampier, B., Descovich, L., Mikula, M., Sultan, A., Schreiber, M., Mikulits, W., Brabletz, T., Strand, D., Obrist, P., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210508 · Cited by 618

Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival

Gjerdrum, C., Tiron, C., Høiby, T., Stefansson, I., Haugen, H., Sandal, T., Collett, K., Li, S., McCormack, E., Gjertsen, B. T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909333107 · Cited by 594

Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients

Yang, Z., Yang, N., Ou, Q., Xiang, Y., Jiang, T., Wu, X., Bao, H., Tong, X., Wang, X., Shao, Y. W., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2310 · Cited by 542

ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatin-remodeling protein BRG1

Sànchez‐Tilló, E., Lázaro, A., Torrent, R., Cuatrecasas, M., Vaquero, E. C., Castells, A., Engel, P., & Postigo, A. A. (2010) · Oncogene · doi:10.1038/onc.2010.102 · Cited by 526

Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway

Kurppa, K. J., Liu, Y., To, C., Zhang, T., Fan, M., Vajdi, A., Knelson, E. H., Xie, Y., Lim, K., Cejas, P., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.006 · Cited by 475

Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways

Arbiser, J. L., Moses, M. A., Fernández, C. A., Ghiso, N., Cao, Y., Klauber, N., Frank, D. A., Brownlee, M., Flynn, E. A., Parangi, S., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.3.861 · Cited by 469

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease

Ohashi, K., Maruvka, Y. E., Michor, F., & Pao, W. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.3912 · Cited by 467

β-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness

Sànchez‐Tilló, E., de Barrios, O., Siles, L., Cuatrecasas, M., Castells, A., & Postigo, A. A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108977108 · Cited by 458

Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal transition

McDonald, O. G., Wu, H., Timp, W., Doi, A., & Feinberg, A. P. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2084 · Cited by 398

Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC

Le, X., Puri, S., Negrao, M. V., Nilsson, M. B., Robichaux, J., Boyle, T., Hicks, J. K., Lovinger, K. L., Roarty, E., Rinsurongkawong, W., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1542 · Cited by 387

Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer

Shah, K. N., Bhatt, R., Rotow, J., Rohrberg, J., Olivas, V., Wang, V. E., Hemmati, G., Martins, M. M., Maynard, A., Kuhn, J., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0264-7 · Cited by 286

YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes

Mizuno, T., Murakami, H., Fujii, M., Ishiguro, F., Tanaka, I., Kondo, Y., Akatsuka, S., Toyokuni, S., Yokoi, K., Osada, H., et al. (2012) · Oncogene · doi:10.1038/onc.2012.5 · Cited by 278

Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non–small cell lung carcinoma

Frederick, B. A., Helfrich, B. A., Coldren, C. D., Zheng, D., Chan, D., Bunn, P. A., & Raben, D. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0138 · Cited by 270

Aurora kinase inhibitors: Progress towards the clinic

Kollareddy, M., Zheleva, D. I., Džubák, P., Brahmkshatriya, P. S., Lepšı́k, M., & Hajdúch, M. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9798-6 · Cited by 242

Suppression of the FOXM1 transcriptional programme via novel small molecule inhibition

Gormally, M. V., Dexheimer, T. S., Marsico, G., Sanders, D. A., Lowe, C. E., Matak‐Vinković, D., Michael, S., Jadhav, A., Rai, G., Maloney, D. J., et al. (2014) · Nature Communications · doi:10.1038/ncomms6165 · Cited by 223

Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo

Ashton, S. E., Song, Y. H., Nolan, J., Cadogan, E. B., Murray, J. A. H., Odedra, R., Foster, J. R., Hall, P. A., Low, S. C., Taylor, P., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad2355 · Cited by 218

Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer

Suda, K., Murakami, I., Katayama, T., Tomizawa, K., Osada, H., Sekido, Y., Maehara, Y., Yatabe, Y., & Mitsudomi, T. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1371 · Cited by 206

A Novel YAP1 Inhibitor Targets CSC-Enriched Radiation-Resistant Cells and Exerts Strong Antitumor Activity in Esophageal Adenocarcinoma

Song, S., Xie, M., Scott, A. W., Jin, J., Ma, L., Dong, X., Skinner, H. D., Johnson, R. L., Ding, S., & Ajani, J. A. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0560 · Cited by 205

Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs

Chung, J.-H., Rho, J. K., Xu, X., Lee, J. S., Yoon, H. I., Lee, C. T., Choi, Y. J., Kim, H.-R., Kim, C. H., & Lee, J. C. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.11.011 · Cited by 186

Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma.

Uramoto, H., Iwata, T., Onitsuka, T., Shimokawa, H., Hanagiri, T., & Oyama, T. (2010) · PubMed · Cited by 168

Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers

Nilsson, M. B., Sun, H., Diao, L., Tong, P., Liu, D., Li, L., Fan, Y., Poteete, A., Lim, S.-O., Howells, K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aao4307 · Cited by 146

FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells

Chiu, W., Huang, Y.-F., Tsai, H.-Y., Chen, C., Chang, C.-H., Huang, S.-C., Hsu, K., & Chou, C.-Y. (2014) · Oncotarget · doi:10.18632/oncotarget.2957 · Cited by 144

AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy

Bertrán-Alamillo, J., Cattan, V., Schoumacher, M., Codony‐Servat, J., Giménez-Capitán, A. A., Cantero, F., Burbridge, M. F., Rodríguez, S., Teixidó, C., Roman, R. A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09734-5 · Cited by 139

FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair

Park, Y., Jung, S. Y., Jennings, N. B., Rodriguez‐Aguayo, C., Peng, G., Lee, S.-R., Kim, S. B., Kim, K., Leem, S.-H., Lin, S., et al. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs167 · Cited by 135

YAP promotes erlotinib resistance in human non-small cell lung cancer cells

Hsu, P., You, B., Yang, Y., Zhang, W., Wang, Y., Xu, Z., Dai, Y., Liu, S., Yang, C., Li, H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10458 · Cited by 121

Reciprocal Regulation of c-Src and STAT3 in Non-Small Cell Lung Cancer

Byers, L. A., Sen, B., Saigal, B., Diao, L., Wang, J., Nanjundan, M., Cascone, T., Mills, G. B., Heymach, J. V., & Johnson, F. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0767 · Cited by 120

YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC

Ghiso, E., Migliore, C., Ciciriello, V., Morando, E., Petrelli, A., Corso, S., Luca, E. D., Gatti, G., Volante, M., & Giordano, S. (2017) · Neoplasia · doi:10.1016/j.neo.2017.10.003 · Cited by 101

ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

Yoshida, T., Song, L., Bai, Y., Kinose, F., Li, J., Ohaegbulam, K. C., Muñoz-Antonia, T., Qu, X., Eschrich, S. A., Uramoto, H., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147344 · Cited by 96

A genetic cell context-dependent role for ZEB1 in lung cancer

Zhang, T., Guo, L., Creighton, C. J., Lü, Q., Gibbons, D. L., Yi, E. S., Deng, B., Molina, J. R., Sun, Z., Yang, P., et al. (2016) · Nature Communications · doi:10.1038/ncomms12231 · Cited by 73

MiR-361-5p suppresses chemoresistance of gastric cancer cells by targeting FOXM1 via the PI3K/Akt/mTOR pathway

Tian, L., Zhao, Z., Xie, L., & Zhu, J. (2017) · Oncotarget · doi:10.18632/oncotarget.23513 · Cited by 71

Proteomic Profiling Identifies Pathways Dysregulated in Non-small Cell Lung Cancer and an Inverse Association of AMPK and Adhesion Pathways with Recurrence

Nanjundan, M., Byers, L. A., Carey, M. S., Siwak, D. R., Raso, M. G., Diao, L., Wang, J., Coombes, K. R., Roth, J. A., Mills, G. B., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f2a266 · Cited by 68

Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas

Lee, T., Tseng, Y.-C., Nguyễn, P. A., Li, Y., Ho, C., & Wu, C.-W. (2018) · Scientific Reports · doi:10.1038/s41598-017-18527-z · Cited by 60

Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial–mesenchymal transition

Lin, S. H., Wang, J., Saintigny, P., Wu, C.-C., Giri, U. P., Zhang, J., Menju, T., Diao, L., Byers, L. A., Weinstein, J. N., et al. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-1079 · Cited by 54

FOXM1 is a downstream target of LPA and YAP oncogenic signaling pathways in high grade serous ovarian cancer

Fan, Q., Cai, Q., & Xu, Y. (2015) · Oncotarget · doi:10.18632/oncotarget.4280 · Cited by 46

SAVANNAH: A Phase II trial of osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-driven (MET+), locally advanced or metastatic non-small cell lung cancer (NSCLC), following disease progression on osimertinib.

Oxnard, G. R., Cantarini, M., Frewer, P., Hawkins, G., Peters, J., Howarth, P., Ahmed, G. F., Sahota, T., Hartmaier, R. J., Li-Sucholeiki, X., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.tps9119 · Cited by 37

Osimertinib in EGFR T790M–Positive Lung Cancer

Mok, T. S., Wu, Y.-L., & Papadimitrakopoulou, V. A. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1703339 · Cited by 35

Mutational Profiling of Non-Small-Cell Lung Cancer Resistant to Osimertinib Using Next-Generation Sequencing in Chinese Patients

Nie, K., Jiang, H., Zhang, C., Geng, C., Xu, X., Zhang, L., Zhang, H., Zhang, Z., Lan, K., & Ji, Y. (2018) · BioMed Research International · doi:10.1155/2018/9010353 · Cited by 35

Loss of NF2 Induces TGFβ Receptor 1–mediated Noncanonical and Oncogenic TGFβ Signaling: Implication of the Therapeutic Effect of TGFβ Receptor 1 Inhibitor on NF2 Syndrome

Cho, J.-H., Oh, A.-Y., Park, S., Kang, S., Yoon, M.-H., Woo, T.-G., Hong, S.-D., Hwang, J., Ha, N., Lee, H., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1210 · Cited by 34

FOXM1 Regulated by ERK Pathway MediatesTGF-1-Induced EMT in NSCLC

Kong, F., Zhu, Y., Yuan, H.-H., Wang, J., Zhao, M., Gong, X., Liu, F., Zhang, W., Wang, C., & Jiang, B. (2014) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504014x14078436004987 · Cited by 33

Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations

Wang, Y., Singh, R., Wang, L., Nilsson, M. B., Goonatilake, R., Tong, P., Li, L., Giri, U. P., Villalobos, P. A., Mino, B., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10332 · Cited by 25

Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation

Zheng, L., Chen, L., Liao, X., Xu, Z., Chen, Z., & Sun, J. (2018) · BMC Cancer · doi:10.1186/s12885-018-4991-4 · Cited by 8

OA14 Phase 2 Study: Tepotinib + Gefitinib in MET+/Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Cheng, Y., Zhou, J., Lü, S., Zhang, Y., Zhao, J., Pan, H., Chen, Y., Chian, C., Bruns, R., Johne, A., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.10.024 · Cited by 2

Artificial intelligence aids in development of nanomedicines for cancer management

Tan, P., Chen, X., Zhang, H., Wei, Q., & Luo, K. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.01.005 · Cited by 256

Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of NF2 -deficient Mesothelioma

Tang, T. T., Konradi, A. W., Feng, Y., Peng, X., Ma, M., Li, J., Yu, F.-X., Guan, K.-L., & Post, L. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0717 · Cited by 245

Coordinating gene expression during the cell cycle

Fischer, M., Schade, A. E., Branigan, T. B., Müller, G. A., & DeCaprio, J. A. (2022) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2022.06.007 · Cited by 218

An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance

Hagenbeek, T. J., Zbieg, J. R., Hafner, M., Mroue, R., Lacap, J. A., Sodir, N. M., Noland, C. L., Afghani, S., Kishore, A., Bhat, K. P., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00577-0 · Cited by 215

Insights into recent findings and clinical application of YAP and TAZ in cancer

Franklin, J. M., Wu, Z., & Guan, K.-L. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00579-1 · Cited by 213

IA34 The YAP/FOXM1 Axis Regulates EMT-Associated EGFR Tyrosine Kinase Inhibitor Resistance and Increased Expression of Spindle Assembly Checkpoint Components

Nilsson, M. B., Sun, H., Robichaux, J. P., Diao, L., Xi, Y., Tong, P., Sheng, L., Hofstad, M. E., Kawakami, M., Le, X., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.12.123 · Cited by 1

Abstract 1960: T790M-independent EGFR TKI resistance is associated with a broad multi-drug resistant phenotype but selective vulnerabilities to spindle assembly complex (SAC) and CDK inhibitors

Nilsson, M. B., Robichaux, J., Sun, H., Tong, P., Diao, L., Hofstad, M. E., Fan, Y.-H., Wang, J., & Heymach, J. V. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-1960

NSCLC depend upon YAP expression and nuclear localization after acquiring resistance to EGFR inhibitors

McGowan, M., Kleinberg, L., Halvorsen, A. R., Helland, Å., & Brustugun, O. T. (2017) · Genes & Cancer · doi:10.18632/genesandcancer.136 · Cited by 65

Drug tolerance and persistence to EGFR inhibitor treatment are mediated by an ILK-SFK-YAP signaling axis in lung adenocarcinoma

Shi, R., Farnsworth, D., Febres‐Aldana, C. A., Chow, J. L. M., Sheena, R., Atwal, T., Marti, J. L. G., Li, S., Thomas, K. N., Lee, C.-M., et al. (2025) · Oncogene · doi:10.1038/s41388-025-03461-6 · Cited by 13

YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC

Ghiso, E., Migliore, C., Ciciriello, V., Morando, E., Petrelli, A., Corso, S., Luca, E. D., Gatti, G., Volante, M., & Giordano, S. (2017) · Neoplasia · doi:10.1016/j.neo.2017.10.003 · Cited by 101